Exiqon Licenses LNA Tech to BD for Use in PCR-Based Infectious Disease Dxs
June 24, 2010
Exiqon Licenses LNA Tech to BD for Use in PCR-Based Infectious Disease Dxs
The licensing agreement marks the first time that a company other than Exiqon will use the locked nucleic acid technology to develop diagnostic products.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- BD, Qiagen, MSKCC, Life Tech, Gen-Probe, Roche, MIT, Smiths Detection and Others Win US Patents
December 1, 2011 / PCR Insider - IP Watch: Recent Patents Related to PCR, Nucleic Acid Amplification, and Sample Prep
May 24, 2011 / PCR Insider - IP Watch: Recent Patents Related to PCR, Nucleic Acid Amplification, and Sample Prep
May 17, 2011 / PCR Insider - IP Watch: Recent Patents Related to PCR, Nucleic Acid Amplification, and Sample Prep
March 2, 2011 / PCR Insider - Cepheid Highlights Strong Uptake of Xpert CT/NG as Q1 Revenues Rise 19 Percent
April 25, 2013 / PCR Insider